
Grifols, S.A. GRFS
$ 8.27
0.49%
Annual report 2024
added 04-18-2026
Grifols, S.A. Operating Cycle 2011-2026 | GRFS
Annual Operating Cycle Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 0.000171 | 261 | 263 | 275 | 282 | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 282 | 0.000171 | 216 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.35 | 0.72 % | $ 3.7 B | ||
|
Galapagos NV
GLPG
|
149 | $ 28.39 | -0.13 % | $ 2.69 B | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 23.42 | -0.3 % | $ 2.98 B | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | ||
|
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 52.38 | -2.24 % | $ 4.71 B | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.64 | 4.46 % | $ 436 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Завод ДИОД
DIOD
|
64.6 | - | - | - | ||
|
Фармсинтез
LIFE
|
9.78 | - | - | - | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B |